Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Regeneron Pharmaceuticals Community
NasdaqGS:REGN Community
3
Narratives
written by author
2
Comments
on narratives written by author
118
Fair Values set
on narratives written by author
Community Investing Ideas
Regeneron Pharmaceuticals
Popular
Undervalued
Overvalued
Regeneron Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 22 Analysts
US Healthcare Reforms And Biosimilars Will Erode Margins
Key Takeaways Reliance on a few key products and increasing biosimilar competition threaten revenue growth and earnings stability as healthcare reforms pressure pricing power. Rising R&D expenses and demographic headwinds may limit the long-term growth potential and sustainability of current revenue streams.
View narrative
US$543.00
FV
0.5% overvalued
intrinsic discount
1.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
3 days ago
author updated this narrative
Regeneron Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 22 Analysts
Dupixent And EYLEA Will Seize Expanding Global Markets
Key Takeaways Regeneron's best-in-class therapies, strong product adoption, and innovative pipeline position it for rapid market share gains and expanded, diversified long-term growth. Strategic investments in manufacturing and advanced biologics platforms enable operational efficiency, robust supply, and capitalize on rising global demand for precision medicines.
View narrative
US$913.96
FV
40.3% undervalued
intrinsic discount
7.59%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
6 days ago
author updated this narrative
Regeneron Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts
Broad Pipeline And Global Access Will Build Future Success
Key Takeaways Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings. Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.
View narrative
US$714.73
FV
23.6% undervalued
intrinsic discount
5.14%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
2
users have commented on this narrative
61
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
REGN
REGN
Regeneron Pharmaceuticals
Your Fair Value
US$
Current Price
US$545.94
14.5% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
19b
2015
2018
2021
2024
2025
2027
2030
Revenue US$18.9b
Earnings US$5.9b
Advanced
Set Fair Value